Comparative effectiveness of different treatment pathways for opioid use disorder.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669 · see citing works

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816 · see citing works

Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017

Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,734 · see citing works

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076 · see citing works

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700 · see citing works

Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014

Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699 · see citing works

The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis

Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677 · see citing works

National and state treatment need and capacity for opioid agonist medication-assisted treatment

Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668 · see citing works

Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial

Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540 · see citing works

Medications for Opioid Use Disorder Save Lives

Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473 · see citing works

Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial

Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415 · see citing works

Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I

Berger, M. L., Mamdani, M., Atkins, D. C., & Johnson, M. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00600.x · Cited by 408 · see citing works

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.001 · Cited by 332 · see citing works

Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5‐Year Update

Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2018) · The Journal of Rural Health · doi:10.1111/jrh.12307 · Cited by 311 · see citing works

Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014

Hadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.0745 · Cited by 295 · see citing works

Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States

Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S., Wakeman, S. E., Freedberg, K. A., Raphel, T. J., Knudsen, A. B., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7621 · Cited by 273 · see citing works

Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial

Hser, Y., Evans, E., Huang, D. Y. C., Weiss, R. A., Saxon, A. J., Carroll, K. M., WOODY, G. E., Liu, D., Wakim, P., Matthews, A. G., et al. (2015) · Addiction · doi:10.1111/add.13238 · Cited by 221 · see citing works

Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence

Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O’Connor, P. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5302 · Cited by 183 · see citing works

HIV Infection and HIV-Associated Behaviors Among Persons Who Inject Drugs — 20 Cities, United States, 2015

Burnett, J. C., Broz, D., Spiller, M. W., Wejnert, C., & Paz‐Bailey, G. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6701a5 · Cited by 180 · see citing works

Notes from the Field: HIV Diagnoses Among Persons Who Inject Drugs — Northeastern Massachusetts, 2015–2018

Cranston, K., Alpren, C., John, B., Dawson, E., Roosevelt, K. A., Burrage, A. B., Bryant, J., Switzer, W. M., Breen, C., Peters, P. J., et al. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6810a6 · Cited by 178 · see citing works

Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort

Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.031 · Cited by 159 · see citing works

Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities

Mojtabai, R., Mauro, C., Wall, M. M., Barry, C. L., & Olfson, M. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05162 · Cited by 158 · see citing works

Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study

Weiss, R. D., Potter, J. S., Griffin, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., Srisarajivakul, E. N., Dodd, D. R., Dreifuss, J. A., McHugh, R. K., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.02.030 · Cited by 146 · see citing works

Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History

Clark, R. E., Baxter, J. D., Aweh, G. N., O’Connell, E., Fisher, W. H., & BARTON, B. A. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.05.001 · Cited by 125 · see citing works

Hospitalizations, Costs, and Outcomes Associated with Heroin and Prescription Opioid Overdoses in the United States 2001–2012

Hsu, D. J., McCarthy, E., Stevens, J., & Mukamal, K. (2017) · Addiction · doi:10.1111/add.13795 · Cited by 106 · see citing works

Thresholds in a low-threshold setting: An empirical study of barriers in a centre for people with drug problems and mental health disorders

Edland-Gryt, M., & Skatvedt, A. H. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2012.08.002 · Cited by 87 · see citing works

Sensitivity analysis for informative censoring in parametric survival models

Siannis, F., Copas, J. B., & Lu, G. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh019 · Cited by 85 · see citing works

Defining a service for people who use drugs as ‘low-threshold’: What should be the criteria?

Islam, M. M., Topp, L., Conigrave, K. M., & Day, C. (2013) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2013.03.005 · Cited by 49 · see citing works

The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence

Clark, R. E., Baxter, J. D., BARTON, B. A., Aweh, G. N., O’Connell, E., & Fisher, W. H. (2014) · Health Services Research · doi:10.1111/1475-6773.12201 · Cited by 48 · see citing works

Patient-centered methadone treatment: a randomized clinical trial

Schwartz, R. P., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O’Grady, K. E., Gandhi, D. H., Olsen, Y. K., & Jaffe, J. H. (2016) · Addiction · doi:10.1111/add.13622 · Cited by 48 · see citing works

The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis

Weir, M. A., Slater, J., Jandoc, R., Koivu, S. L., Garg, A. X., & Silverman, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180694 · Cited by 47 · see citing works

County‐level access to opioid use disorder medications in medicare Part D (2010‐2015)

Abraham, A. J., Adams, G. B., Bradford, A. C., & Bradford, W. D. (2019) · Health Services Research · doi:10.1111/1475-6773.13113 · Cited by 46 · see citing works

Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs

Andrews, C. M., Abraham, A. J., Grogan, C. M., Westlake, M. A., Pollack, H. A., & Friedmann, P. D. (2019) · American Journal of Public Health · doi:10.2105/ajph.2018.304856 · Cited by 43 · see citing works

Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse

Wollschlaeger, B., Willson, T. M., Montejano, L. B., Ronquest, N. A., & Nadipelli, V. R. (2017) · Journal of Opioid Management · doi:10.5055/jom.2017.0389 · Cited by 24 · see citing works

Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.

Wittenberg (2016) · Addiction · doi:10.1111/add.v111.4 · Cited by 13 · see citing works

Brief Report: Nonfatal Overdose Events Among Persons Who Inject Drugs: Findings From Seven National HIV Behavioral Surveillance Cities 2009 & 2012

Robinson, W. T., Kazbour, C., Nassau, T., Fisher, K. A., Sheu, S. U., Rivera, A. V., Al‐Tayyib, A., Glick, S. N., Braunstein, S., Barak, N., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001426 · Cited by 8 · see citing works

Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States

Goedel, W. C., Shapiro, A. M., Cerdá, M., Tsai, J. W., Hadland, S. E., & Marshall, B. D. L. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3711 · Cited by 298 · see citing works

Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019

Mauro, P. M., Gutkind, S., Annunziato, E. M., & Samples, H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3821 · Cited by 226 · see citing works

The opioid crisis: a contextual, social-ecological framework

Jalali, M. S., Botticelli, M. P., Hwang, R. C., Koh, H. K., & McHugh, R. K. (2020) · Health Research Policy and Systems · doi:10.1186/s12961-020-00596-8 · Cited by 218 · see citing works

Racial Inequality in Receipt of Medications for Opioid Use Disorder

Barnett, M. L., Meara, E. R., Lewinson, T., Hardy, B., Chyn, D., Onsando, W. M., Huskamp, H. A., Mehrotra, A., & Morden, N. E. (2023) · New England Journal of Medicine · doi:10.1056/nejmsa2212412 · Cited by 190 · see citing works

Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review

Madden, E. F., Prevedel, S. M., Light, T., & Sulzer, S. H. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1975749 · Cited by 178 · see citing works

The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study

Winhusen, T. M., Walley, A. Y., Fanucchi, L. C., Hunt, T., Lyons, M., Lofwall, M. R., Brown, J. L., Freeman, P. R., Nunes, E. V., Beers, D., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108325 · Cited by 133 · see citing works

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department

Hawk, K. F., Hoppe, J. A., Ketcham, E. M., LaPietra, A. M., Moulin, A. K., Nelson, L. S., Schwarz, E. S., Shahid, S., Stader, D. E., Wilson, M. P., et al. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.04.023 · Cited by 125 · see citing works

An overdose surge will compound the COVID-19 pandemic if urgent action is not taken

Wakeman, S. E., Green, T. C., & Rich, J. D. (2020) · Nature Medicine · doi:10.1038/s41591-020-0898-0 · Cited by 121 · see citing works

Outcomes associated with the use of medications for opioid use disorder during pregnancy

Krans, E. E., Kim, J. Y., Chen, Q., Rothenberger, S. D., James, A. E., Kelley, D., & Jarlenski, M. (2021) · Addiction · doi:10.1111/add.15582 · Cited by 120 · see citing works

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl

Chambers, L. C., Hallowell, B. D., Zullo, A. R., Paiva, T. J., Berk, J., Gaither, R., Hampson, A. J., Beaudoin, F. L., & Wightman, R. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.34540 · Cited by 122 · see citing works

Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse

Lagisetty, P., Garpestad, C., Larkin, A., Macleod, C., Antoku, D., Slat, S., Thomas, J., Powell, V. D., Bohnert, A. S. B., & Lin, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108583 · Cited by 102 · see citing works

Opioid Use Disorder

Taylor, J. L., & Samet, J. H. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202201180 · Cited by 95 · see citing works

Disparities by Sex and Race and Ethnicity in Death Rates Due to Opioid Overdose Among Adults 55 Years or Older, 1999 to 2019

Mason, M., Soliman, R., Kim, H. S., & Post, L. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42982 · Cited by 92 · see citing works

Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder

Andraka‐Christou, B. (2021) · Health Affairs · doi:10.1377/hlthaff.2020.02261 · Cited by 91 · see citing works

Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program

Snyder, H. R., Kalmin, M. M., Moulin, A. K., Campbell, A., Goodman‐Meza, D., Padwa, H., Clayton, S., Speener, M., SHOPTAW, S. J., & Herring, A. A. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.05.024 · Cited by 94 · see citing works

“You’re Not Supposed to be on it Forever”: Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids

Dickson‐Gómez, J., Spector, A. L., Weeks, M. R., Galletly, C. L., McDonald, M. J., & Montaque, H. D. G. (2022) · Substance Abuse Research and Treatment · doi:10.1177/11782218221103859 · Cited by 91 · see citing works

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis

Qeadan, F., McCunn, A., & Tingey, B. (2025) · Addiction · doi:10.1111/add.16679 · Cited by 90 · see citing works

Opioid use disorder treatment for people experiencing homelessness: A scoping review

McLaughlin, M. F., Li, R., Carrero, N. D., Bain, P. A., & Chatterjee, A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108717 · Cited by 90 · see citing works

Exploring patient medication adherence and data mining methods in clinical big data: A contemporary review

Xu, Y., Zheng, X., Li, Y., Ye, X., Cheng, H., Wang, H., & Lyu, J. (2023) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12548 · Cited by 96 · see citing works

The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review

Frost, M. C., Lampert, H., Tsui, J. I., Iles-Shih, M., & Williams, E. C. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00266-2 · Cited by 82 · see citing works

Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19

Tiako, M. J. N. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108214 · Cited by 76 · see citing works

Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl

Englander, H. L., Thakrar, A. P., Bagley, S. M., Rolley, T., Dong, K. A., & Hyshka, E. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.7282 · Cited by 78 · see citing works

Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US

Stahler, G. J., Mennis, J. L., & Baron, D. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108849 · Cited by 74 · see citing works

Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review

Chan, B. L., Gean, E. G., Arkhipova-Jenkins, I., Gilbert, J., Hilgart, J., Fiordalisi, C. V., Hubbard, K., Brandt, I., Stoeger, E., Paynter, R. A., et al. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000739 · Cited by 73 · see citing works

Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis

Stringfellow, E. J., Lim, T. Y., Humphreys, K. N., DiGennaro, C., Stafford, C. A., Beaulieu, É., Homer, J. B., Wakeland, W. W., Bearnot, B. I., McHugh, R. K., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8147 · Cited by 73 · see citing works

Projected estimates of opioid mortality after community-level interventions.

Linas, B. P., Savinkina, A., Madushani, R. W. M. A., Wang, J., Eftekhari Yazdi, G., Chatterjee, A., Walley, A. Y., Morgan, J. R., Epstein, R. L., Assoumou, S. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37259 · Cited by 72 · see citing works

Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108764 · Cited by 67 · see citing works

Duration of medication treatment for opioid‐use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study

Burns, M. E., Tang, L., Chang, C. H., Kim, J. Y., Ahrens, K. A., Allen, L., Cunningham, P. J., Gordon, A. J., Jarlenski, M., Lanier, P., et al. (2022) · Addiction · doi:10.1111/add.15959 · Cited by 67 · see citing works

Therapies Offered at Residential Addiction Treatment Programs in the United States

Beetham, T., Saloner, B. K., Gaye, M., Wakeman, S. E., Frank, R. G., & Barnett, M. L. (2020) · JAMA · doi:10.1001/jama.2020.8969 · Cited by 66 · see citing works

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic

Frost, M. C., Zhang, L., Kim, H. M., & Lin, L. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36298 · Cited by 64 · see citing works

Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic

Hailu, R., Mehrotra, A., Huskamp, H. A., Busch, A. B., & Barnett, M. L. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.52381 · Cited by 63 · see citing works

Mental Health and Psychosocial Needs of Patients Being Treated for Opioid Use Disorder in a Primary Care Residency Clinic

Hooker, S. A., Sherman, M. D., Lonergan, M. E., Sattler, A. F., Liese, B. S., Justesen, K., Nissly, T. J., & Levy, R. J. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720932017 · Cited by 62 · see citing works

Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use

Streed, C. G., Morgan, J. R., Gai, M. J., Larochelle, M. R., Paasche‐Orlow, M. K., & Taylor, J. L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.21346 · Cited by 60 · see citing works

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic

Nguyen, T. D., Ziedan, E., Simon, K. I., Miles, J., Crystal, S., Samples, H., & Gupta, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14765 · Cited by 59 · see citing works

One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission

Stone, A. C., Carroll, J. J., Rich, J. D., & Green, T. C. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108031 · Cited by 58 · see citing works

Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities

Pasman, E., Kollin, R., Broman, M. J., Lee, G., Agius, E., Lister, J. J., Brown, S., & Resko, S. M. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00316-3 · Cited by 60 · see citing works

Buprenorphine Field Initiation of ReScue Treatment by Emergency Medical Services (Bupe FIRST EMS): A Case Series

Carroll, G. G., Wasserman, D. D., Shah, A., Salzman, M., Baston, K., Rohrbach, R., Jones, I., & Haroz, R. (2020) · Prehospital Emergency Care · doi:10.1080/10903127.2020.1747579 · Cited by 56 · see citing works

Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?

Nunes, E. V., LEVIN, F. R., Reilly, M. P., & El‐Bassel, N. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108196 · Cited by 56 · see citing works

Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder

Jones, K. F., Khodyakov, D., Arnold, R. M., Bulls, H. W., Dao, E., Kapo, J. M., Meier, D. E., Paice, J. A., Liebschutz, J. M., Ritchie, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2191 · Cited by 56 · see citing works

Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine

Calcaterra, S. L., Martín, M., Bottner, R., Englander, H. L., Weinstein, Z., Weimer, M. B., Lambert, E., & Herzig, S. J. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12893 · Cited by 57 · see citing works

Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails

Flanagan, E. A., Ducharme, L. J., Taylor, B. G., Lamuda, P. A., Kolak, M., Friedmann, P. D., Pollack, H. A., & Schneider, J. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.34704 · Cited by 56 · see citing works

Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials

Lim, J., Farhat, I., Douros, A., & Panagiotoglou, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266142 · Cited by 56 · see citing works

Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review

Guillen, A., Reddy, M., Saadat, S., & Chakravarthy, B. (2021) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2021.0308 · Cited by 54 · see citing works

Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic

Velez, F. F., Colman, S., Kauffman, L., Ruetsch, C. R., & Anastassopoulos, K. P. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1840357 · Cited by 55 · see citing works

Stigmatization of Medications for Opioid use Disorder in 12-Step Support Groups and Participant Responses

Andraka‐Christou, B., Totaram, R., & Randall-Kosich, O. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1944957 · Cited by 52 · see citing works

A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Haffajee, R. L., Andraka‐Christou, B., Attermann, J., Cupito, A., Buche, J., & Beck, A. J. (2020) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-020-00312-3 · Cited by 51 · see citing works

Telehealth Utilization Is Associated with Lower Risk of Discontinuation of Buprenorphine: a Retrospective Cohort Study of US Veterans

Vakkalanka, J. P., Lund, B. C., Ward, M. M., Arndt, S. V., Field, R. W., Charlton, M. E., & Carnahan, R. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06969-1 · Cited by 51 · see citing works

Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.

Frost, M. C., Sweek, E. W., Austin, E. J., Corcorran, M. A., Juarez, A. M., Frank, N. D., Prohaska, S. M., LaKosky, P. A., Asher, A. K., Broz, D., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03332-7 · Cited by 49 · see citing works

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot

Hern, H. G., Lara, V., Goldstein, D., Kalmin, M. M., Kidane, S., SHOPTAW, S. J., Tzvieli, O., & Herring, A. A. (2022) · Prehospital Emergency Care · doi:10.1080/10903127.2022.2061661 · Cited by 49 · see citing works

An Evaluation of Opioid Use in Black Communities: A Rapid Review of the Literature

Jordan, A., Mathis, M. L., Haeny, A. M., Funaro, M. C., Paltin, D., & Ransome, Y. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000285 · Cited by 49 · see citing works

Insurance barriers to substance use disorder treatment after passage of mental health and addiction parity laws and the affordable care act: A qualitative analysis

Dickson‐Gómez, J., Weeks, M. R., Green, D., Boutouis, S., Galletly, C. L., & Christenson, E. A. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100051 · Cited by 48 · see citing works

Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services

Carroll, G. G., Solomon, K. T., Heil, J., Saloner, B. K., Stuart, E. A., Patel, E., Greifer, N., Salzman, M., Murphy, E. M., Baston, K., et al. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.07.006 · Cited by 47 · see citing works

Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone

Carl, A., Pasman, E., Broman, M. J., Lister, J. J., Agius, E., & Resko, S. M. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100138 · Cited by 47 · see citing works

A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs

Hawk, K. F., Grau, L. E., Fiellin, D. A., Chawarski, M. C., O’Connor, P. G., Cirillo, N., Breen, C., & D’Onofrio, G. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14197 · Cited by 46 · see citing works

Causes of Death in the 12 Months After Hospital Discharge Among Patients With Opioid Use Disorder

King, C., Cook, R., Korthuis, P. T., Morris, C. D., & Englander, H. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000915 · Cited by 46 · see citing works

Multidisciplinary Treatment of Opioid use Disorder in Primary Care using the Collaborative Care Model

Brackett, C. D., Duncan, M. S., Wagner, J. F., Fineberg, L., & Kraft, S. A. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1932698 · Cited by 45 · see citing works

Medicaid Expansion Increased Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies

Khatri, U. G., Howell, B. A., & Winkelman, T. N. A. (2021) · Health Affairs · doi:10.1377/hlthaff.2020.01251 · Cited by 43 · see citing works

Awareness, perception and utilization of a mobile health clinic by people who use drugs

Grieb, S. M. D., Harris, R., Rosecrans, A. M., Zook, K. J. C., Sherman, S. G., Greenbaum, A. H., Lucas, G. M., & Page, K. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2021.2022188 · Cited by 44 · see citing works

Mobile low-threshold buprenorphine integrated with infectious disease services

Rosecrans, A. M., Harris, R., Saxton, R. E., Cotterell, M., Zoltick, M., Willman, C., Blackwell, I., Bell, J., Hayes, D., Weir, B. W., et al. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108553 · Cited by 44 · see citing works

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study

Gomes, T., McCormack, D., Bozinoff, N., Tadrous, M., Antoniou, T., Munro, C., Campbell, T. J., Paterson, J. M., Mamdani, M., & Sproule, B. A. (2022) · Addiction · doi:10.1111/add.15862 · Cited by 43 · see citing works

Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care

Abraham, A. J., Andrews, C. M., Harris, S. J., Westlake, M. A., & Grogan, C. M. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.4001 · Cited by 43 · see citing works

Emergency Department Access to Buprenorphine for Opioid Use Disorder

Herring, A. A., Rosen, A. D., Samuels, E. A., Lin, C., Speener, M., Kaleekal, J., SHOPTAW, S. J., Moulin, A. K., Campbell, A., Anderson, E. S., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.53771 · Cited by 43 · see citing works

A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations

Husain, J. M., Cromartie, D., Fitzelle-Jones, E., Brochier, A., Borba, C. P. C., & Montalvo, C. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108918 · Cited by 42 · see citing works

Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States

Chhatwal, J., Mueller, P. P., Chen, Q., Kulkarni, N. S., Adee, M. G., Zarkin, G. A., Larochelle, M. R., Knudsen, A. B., & Barbosa, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14925 · Cited by 42 · see citing works

What Obstetrician–Gynecologists Should Know About Substance Use Disorders in the Perinatal Period

Smid, M. C., & Terplan, M. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004657 · Cited by 44 · see citing works

Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term SM) communities study

Chandler, R. K., Nunes, E. V., Tan, S., Freeman, P. R., Walley, A. Y., Lofwall, M. R., Oga, E. A., Glasgow, L., Brown, J. L., Fanucchi, L. C., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109804 · Cited by 41 · see citing works

Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review

Peckham, A. M., & Young, E. H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa503 · Cited by 41 · see citing works

Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting

Morgan, J. R., Barocas, J. A., Murphy, S. M., Epstein, R. L., Stein, M. D., Schackman, B. R., Walley, A. Y., & Linas, B. P. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29676 · Cited by 40 · see citing works

Rewarding recovery: the time is now for contingency management for opioid use disorder

Proctor, S. L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2068805 · Cited by 39 · see citing works

Envisioning Minimally Disruptive Opioid Use Disorder Care

Englander, H. L., Gregg, J. L., & Levander, X. A. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07939-x · Cited by 38 · see citing works

Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats

Urbanik, L. A., Acharya, N., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.023 · Cited by 38 · see citing works

Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series

Peckham, A. M., Kehoe, L. G., Gray, J. R., & Wakeman, S. E. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108316 · Cited by 37 · see citing works

Racial/ethnic disparities in the availability of hospital based opioid use disorder treatment

Chang, J. E., Franz, B. A., Cronin, C. E., Lindenfeld, Z., Lai, A. Y., & Pagán, J. A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108719 · Cited by 37 · see citing works

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Coon, S. A., Hill, L. G., Hutchison, R. W., Arnold, L. M., Jarrett, J. B., Ottney, A. R., Oung, A. B., Painter, N. A., Smith, M. A., Stranges, P. M., et al. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1331 · Cited by 36 · see citing works

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment

Nunes, E. V., Scodes, J. M., Pavlicová, M., Lee, J. D., Novo, P., Campbell, A. N. C., & Rotrosen, J. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060816 · Cited by 36 · see citing works

Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago

Messmer, S. E., Elmes, A. T., Jimenez, A. D., Murphy, A. L., Guzman, M., Watson, D. P., Poorman, E. A., Mayer, S., Infante, A. F., Keller, E., et al. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209054 · Cited by 35 · see citing works

Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections

Barocas, J. A., Gai, M. J., Amuchi, C. B., Jawa, R., & Linas, B. P. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108207 · Cited by 35 · see citing works

Western Journal of Emergency Medicine

Do, N., & Saucedo, C. (2022) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2022.5.2022 · Cited by 35 · see citing works

Neuroimmune Mechanisms of Opioid Use Disorder and Recovery: Translatability to Human Studies, and Future Research Directions

Butelman, E. R., Goldstein, R. Z., Nwaneshiudu, C. A., Girdhar, K., Roussos, P., Russo, S. J., & Alia‐Klein, N. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.07.031 · Cited by 34 · see citing works

Disparities in Addiction Treatment

Jackson, D. S., Tiako, M. J. N., & Jordan, A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.008 · Cited by 41 · see citing works

Medication for opioid use disorder service delivery in carceral facilities: update and summary report

Berk, J., South, A.-M., Martin, M. S., James, M.-E., Miller, C., Haber, L. A., & Rich, J. D. (2025) · Health & Justice · doi:10.1186/s40352-025-00317-9 · Cited by 33 · see citing works

A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation

Wakeman, S. E., Kane, M. T., Powell, E. A., Howard, S., Shaw, C. J., Kehoe, L., Rosen, J. B., Quinlan, J., & Regan, S. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1846664 · Cited by 33 · see citing works

Admission Practices And Cost Of Care For Opioid Use Disorder At Residential Addiction Treatment Programs In The US

Beetham, T., Saloner, B. K., Gaye, M., Wakeman, S. E., Frank, R. G., & Barnett, M. L. (2021) · Health Affairs · doi:10.1377/hlthaff.2020.00378 · Cited by 33 · see citing works

The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill

Nguyen, T. D., Muench, U., Andraka‐Christou, B., Simon, K. I., Bradford, W. D., & Spetz, J. (2021) · Medical Care Research and Review · doi:10.1177/10775587211004311 · Cited by 33 · see citing works

Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder

Parlier‐Ahmad, A. B., Pugh, M., & Martin, C. E. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01095-4 · Cited by 33 · see citing works

Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020

Cantor, J., Powell, D., Kofner, A., & Stein, B. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109107 · Cited by 33 · see citing works

Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention

Drainoni, M., Knudsen, H. K., Adams, K., Andrews-Higgins, S., Auritt, V., Back, S., Barkowski, L. K., Batty, E. J., Behrooz, M. R., Bell, S., et al. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108731 · Cited by 33 · see citing works

The harms of punishing substance use during pregnancy

Carroll, J. J., El‐Sabawi, T., & Ostrach, B. M. M. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103433 · Cited by 32 · see citing works

“Sick and tired of being sick and tired”: Exploring initiation of medications for opioid use disorder among people experiencing homelessness

Swartz, N., Adnan, T., Peréa, F. C., Baggett, T. P., & Chatterjee, A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108752 · Cited by 32 · see citing works

Negative attitudes about medications for opioid use disorder among criminal legal staff

Moore, K. E., Siebert, S. L., Kromash, R., Owens, M. D., & Allen, D. C. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100056 · Cited by 32 · see citing works

Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities

Osterhage, K. P., Hser, Y., Mooney, L. J., Sherman, S. J., Saxon, A. J., Ledgerwood, M., Holtzer, C. C., Gehring, M. A., Clingan, S. E., Curtis, M. E., et al. (2023) · Addiction · doi:10.1111/add.16338 · Cited by 31 · see citing works

Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17

Heimer, R., Black, A. C., Lin, H., Grau, L. E., Fiellin, D. A., Howell, B. A., Hawk, K. F., D’Onofrio, G., & Becker, W. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111040 · Cited by 31 · see citing works

Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose

Harris, M. T. H., Weinstein, Z., & Walley, A. Y. (2026) · JAMA · doi:10.1001/jama.2025.26348 · Cited by 31 · see citing works

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

Peckham, A. M., Ball, J., Colvard, M. D., Dadiomov, D., Hill, L. G., Nichols, S. D., Tallian, K. B., Ventricelli, D. J., & Tran, T. H. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab003 · Cited by 31 · see citing works

Opioid Use Disorder: Treatments and Barriers

Patel, K., Bunachita, S., Agarwal, A. A., Lyon, A., & Patel, U. K. (2021) · Cureus · doi:10.7759/cureus.13173 · Cited by 33 · see citing works

Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description

Regan, S., Howard, S., Powell, E., Martin, A., Dutta, S., Hayes, B. D., White, B. A., Williamson, D., Kehoe, L., Raja, A. S., et al. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000875 · Cited by 31 · see citing works

Treatment preference for opioid use disorder among people who are incarcerated

Kaplowitz, E. R., Truong, A. Q., Berk, J., Martin, R. A., Clarke, J. G., Wieck, M., Rich, J. D., & Brinkley‐Rubinstein, L. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108690 · Cited by 31 · see citing works

Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design

Morgan, J. R., Quinn, E. K., Chaisson, C. E., Ciemins, E., Stempniewicz, N., White, L. F., Linas, B. P., Walley, A. Y., & LaRochelle, M. R. (2022) · Medical Care · doi:10.1097/mlr.0000000000001689 · Cited by 30 · see citing works

Acceptance of medications for opioid use disorder in recovery housing programs in Missouri

Wood, C. A., Duello, A., Miles, J., Lohmann, B., Gochez‐Kerr, T., Richardson, K., Anderson-Harper, R., & Winograd, R. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108747 · Cited by 30 · see citing works

Models for Implementing Emergency Department–Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers

Whiteside, L., D’Onofrio, G., Fiellin, D. A., Edelman, E. J., Richardson, L. D., O’Connor, P. G., Rothman, R. E., Cowan, E. A., Lyons, M. S., Fockele, C. E., et al. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.05.010 · Cited by 30 · see citing works

Treatment Pathways for Opioid Use Disorder in Commercially-Insured United States Adults from 2010-2019

Saini, J., Qato, D. M., Rizk, J. G., DiPaula, B. A., Ehret, M. J., Pathan, U., & Johnson, A. M. (2026) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.25-00480

Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting

Morgan, J. R., Barocas, J. A., Murphy, S. M., Epstein, R. L., Stein, M. D., Schackman, B. R., Walley, A. Y., & Linas, B. P. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29676 · Cited by 40 · see citing works

Comparative study shows superiority of medications for opioid use disorder

(2020) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30582

Real-world longitudinal treatment trajectories following opioid use disorder diagnosis among commercially insured beneficiaries in the United States

Rizk, J. G., Qato, D. M., Saini, J., Pathan, U., DiPaula, B. A., Ehret, M. J., Johnson, A. M., & Li, Y. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209858 · Cited by 1 · see citing works

Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey

Lee, S., Sun, L. L., & Vakkalanka, J. P. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.05.015 · Cited by 4 · see citing works